0000000001182390

AUTHOR

Stefano Fichera

showing 1 related works from this author

Widening use of dexamethasone implant for the treatment of macular edema

2017

Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo Department of Ophthalmology, University of Catania, Catania, Italy Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of effica…

3003intravitrealgenetic structuresimplantmedicine.medical_treatmentPharmaceutical ScienceVitrectomyReviewDrug Implantcorticosteroids0302 clinical medicineGlucocorticoidCentral retinal vein occlusionDrug DiscoveryDelayed-Action PreparationCorticosteroidRandomized Controlled Trials as TopicDrug ImplantsCorticosteroids; Dexamethasone; Implant; Intravitreal; Macular edema; Pharmacology; 3003; Drug Discovery3003 Pharmaceutical ScienceDiabetic retinopathyIntravitreal InjectionsUveitismedicine.drugHumanmedicine.medical_specialtydexamethasone03 medical and health sciencesOphthalmologymedicineHumansMacular edemaGlucocorticoidsDexamethasonePharmacologyMacular edemaDiabetic Retinopathybusiness.industryIntravitreal InjectionDrug Discovery3003 Pharmaceutical Sciencelcsh:RM1-950Macular degenerationmedicine.diseaseeye diseasesSurgerylcsh:Therapeutics. PharmacologyDelayed-Action Preparations030221 ophthalmology & optometryBranch retinal vein occlusionsense organsbusiness030217 neurology & neurosurgeryDrug Design, Development and Therapy
researchProduct